Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.81 |
| ▸ | DRD2 | P14416 | 1/20 | 0.81 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.81 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.81 |
| ▸ | CNR1 | P21554 | 1/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.81 |
| ▸ | HTR2A | P28223 | 1/20 | 0.81 |
| ▸ | HTR2C | P28335 | 1/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.81 |
| ▸ | HRH1 | P35367 | 1/20 | 0.81 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.81 |
| ▸ | DRD3 | P35462 | 1/20 | 0.81 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.81 |
| ▸ | HTR2B | P41595 | 1/20 | 0.81 |
| ▸ | HTT | P42858 | 1/20 | 0.81 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomerizine SCHEMBL79390 | 0.90 | LMNA (1.00) | LMNACHRM2ADORA3CHRM1DRD2 | |
| Lomerizine SCHEMBL29496366 | 0.90 | LMNA (1.00) | LMNACHRM2ADORA3CHRM1DRD2 | |
| Lomerizine SCHEMBL404179 | 0.88 | LMNA (0.98) | LMNACHRM2ADORA3CHRM1DRD2 | |
| Lomerizine SCHEMBL1153647 | 0.88 | LMNA (0.98) | LMNACHRM2ADORA3CHRM1DRD2 | |
| Lomerizine SCHEMBL29439945 | 0.88 | LMNA (0.98) | LMNACHRM2ADORA3CHRM1DRD2 | |
| Lomerizine SCHEMBL1650277 | 0.87 | LMNA (0.95) | LMNACHRM2ADORA3CHRM1DRD2 | |
| SCHEMBL1152274 | 0.85 | LMNA (0.91) | LMNACHRM2ADORA3CHRM1DRD2 | |
| Hydrochloric Acid SCHEMBL7324923 | 0.84 | LMNA (0.89) | LMNACHRM2ADORA3CHRM1DRD2 | |
| SCHEMBL21186331 | 0.84 | LMNA (0.76) | LMNACHRM2ADORA3CHRM1DRD2 | |
| Lomerizine SCHEMBL10731150 | 0.83 | LMNA (0.82) | LMNACHRM2ADORA3CHRM1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1277746-B1 | N-benzylpiperazine derivatives, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2005-05-11 | — | — | EP | disclosed |
| US-6686360-B2 | ANTIISCHEMIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2004-02-03 | — | — | US | disclosed |
| US-20030158207-A1 | N-benzylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2003-08-21 | — | — | US | disclosed |
| EP-1277746-A2 | N-benzylpiperazine derivatives, process for their preparation and pharmaceutical compositions thereof | Les Laboratoires Servier (FR) | 2003-01-22 | — | — | EP | disclosed |
| EP-0847999-B1 | N-benzylpiperazine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2001-03-21 | — | — | EP | disclosed |
| EP-0617027-B1 | N-Benzylpiperazinderivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2000-06-07 | — | — | EP | disclosed |
| US-5849745-A | N-benzylpiperazine compounds | ADIR ET COMPAGNIE (FR) | 1998-12-15 | — | — | US | disclosed |
| EP-0847999-A1 | N-benzylpiperazine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-06-17 | — | — | EP | disclosed |
| US-5492913-A | TREATING NEURONAL DISORDERS RESULTING FROM DYSFUNCTION OF OXIDATIVE METABOLISM | ADIR ET COMPAGNIE (FR) | 1996-02-20 | — | — | US | disclosed |
| EP-0617027-A1 | N-Benzylpiperazinderivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158207-A1 | N-benzylpiperazine compounds | NPPA, BAD, GLS | LMNA 1289/4885CHRM2 1944/4885ADORA3 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.